Abstract:Objective To evaluate the impact of rosiglitazone (Ros) on liver expression of peroxisome proliferator-activated receptor γ (PPARγ),nuclear factor (NF-κB) and cyclooxygenase-2(COX-2) in treatment of nonalcoholic steatohepatitis (NASH) rats.Methods Thirty Sprague-Dawley rats were divided into normal group,model group and Ros treated group with 10 each.Except the normal group,the other two groups were given high fat diet for 12 weeks for NASH model.The rats in Ros treated group were gavaged 4 mg/kg of Ros daily at the 12th week for 8 weeks.All rats were sacrificed at the 20th week for blood sample and liver tissue.Biochemical parameters of liver function,lipid metabolism,glycometabolism and antioxidant enzyme activities were measured.The histological change of the liver were assessed with HE and Masson staining.The level of tumor necrosis factor (TNF)-α and prostaglandin E2 (PGE2) was measured using ELISA.The expression of PPARγ,NF-κB and COX-2 was detected with immunohistochemistry.The mRNA and protein expressions of COX-2 were tested by real-time PCR and Western blotting,respectively.Results In comparison with model group,Ros treated group showed significant improvement in hepatic steatosis,inflammation and fibrosis(all P value<0.05).In model group,the serum levels of fasting blood glucose,insulin and HOMA-insulin resistance index (HOMA-IRI),total cholesterol (TC),total triglyeride (TG),lowdensity lipoprotein cholesterol (LDL-C) and free fatty acids were increased,but HDL-C level was decreased.All above parameters markedly improved after Ros treatment.The levels of ALT and AST,total anti-oxidation competence,superoxide dismutase,catalase,glutathione peroxidase and malondialdehyde in Ros treated group were significantly ameliorated when compared with those in model group.Immunohistochemistry showed that the expression of NF-κB and COX-2 was significantly elevated,but PPARγ was decreased in model group.Real-time PCR and Western blot revealed that the mRNA and protein expressions of COX-2 were higher in the model group than those in normal group (0.57±0.08 vs 0.38±0.03;2.83±0.24 vs 1.00±0.03,P=0.000 and P=0.004,respectively),but significantly lower in Ros treated group (0.55±0.06 and 1.84±0.13,P<0.01).Conclusions Ros can reduce oxidative stress and insulin resistance in NASH rats by activing PPARγ expression and inhibiting expression of NF-κB and cyclooxygenases.

Effect of Rosiglitazone on Hydrogen Peroxide-Induced Pig's Endothelial Cell Apoptosis

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Rosiglitazone Attenuates Hyperglycemia-Enhanced Hemorrhagic Transformation after Transient Focal Ischemia in Rats.

Rosiglitazone Via PPARγ-dependent Suppression of Oxidative Stress Attenuates Endothelial Dysfunction in Rats Fed Homocysteine Thiolactone.

[PPAR Gamma Agonist Rosiglitazone Alleviates Hypoxia/reoxygenation-Induced Oxidative Stress and Apoptosis in Rat Cardiac Myocytes].

Protective Effects of Rosiglitazone on Non-Alcoholic Steatohepatitis in Rats

Rosiglitazone Inhibits High Glucose-Induced Apoptosis in Human Umbilical Vein Endothelial Cells Through the PI3K/Akt/eNOS Pathway

The Effect of Rosiglitazone in Modulating Cyclooxygenases-2 in Nonalcoholic Steatohepatitis Rats

Effects of Rosiglitazone on Lipid Peroxidation in Nonalcoholic Steatohepatitis Rats

Effects of Peroxisome Proliferator-Activated Receptor Γ Activator Rosiglitazone on Myocardial Ischemic-Reperfusion Injury in Rats

Pioglitazone Protect PC12 Cells Against Oxidative Stress Injury: Involvement of Anti-apoptotic Effect and PPARγ Activation

Influence of rosiglitazone on the expression of peroxisome proliferator-activated receptor gamma and endothelin-1 in human umbilical vein endothelial cells cultured in vitro

Protective effect of rosiglitazone on cardiomyocytes injured by ET-1 and its mechanism

Protective Effects of Rosiglitazone on Retinal Neuronal Damage in Diabetic Rats

Protective effect of rosiglitazone on endothelial cells and endogenous nitric oxide synthase inhibitor in diabetic rats

Effect of rosiglitazone on adhesion molecule expression of lung injury in rats with acute pancreatitis

Rosiglitazone attenuates hypoxia-induced renal cell apoptosis by inhibiting NF-κB signaling pathway in a PPARγ-dependent manner

Effection and mechanism of rosiglitazone on vascular restenosis in rats

Effects Of Rosiglitazone, An Agonist Of The Peroxisome Proliferator-Activated Receptor Gamma, On Intestinal Damage Induced By Escherichia Coli Lipopolysaccharide In Weaned Pigs